Literature DB >> 25966423

Epidemiology of cholangiocarcinoma.

Annika Bergquist1, Erik von Seth2.   

Abstract

Cholangiocarcinoma (CCA) is a cancer arising from the intra- or extrahepatic bile ducts and mainly characterized by its late diagnosis and fatal outcome. CCA is the second most common primary liver tumour and accounts for approximately 10-15% of all hepatobiliary malignancies. The development of CCA is linked to a wide spectrum of conditions causing biliary inflammation, cholestasis and inflammation of the liver. The geographic diversity of risk factors is reflected in considerable differences in incidence worldwide. Although data are not consistent, incidence seems to be rising in the Western World. Given the limited opportunities of treating advanced CCA, surveillance has been suggested as a strategy for detection of early disease in the high-risk group of patients with primary sclerosing cholangitis (PSC). In this review we present an updated overview of the epidemiology of CCA. We also highlight the risk of CCA in PSC with special focus on surveillance strategies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biliary cytology; Cholangiocarcinoma; Epidemiology; Primary sclerosing cholangitis; Risk factors

Mesh:

Year:  2015        PMID: 25966423     DOI: 10.1016/j.bpg.2015.02.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  118 in total

1.  Recurrent Cholangiocarcinoma Presenting as Sister Mary Joseph Nodule After Liver Transplantation.

Authors:  Vijayadershan Muppidi; Sreenath Meegada; James D Eason; Satheesh P Nair; Rajanshu Verma
Journal:  Cureus       Date:  2020-11-24

2.  MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma.

Authors:  Adrian P Mansini; Maria J Lorenzo Pisarello; Kristen M Thelen; Maetzin Cruz-Reyes; Estanislao Peixoto; Sujeong Jin; Brynn N Howard; Christy E Trussoni; Gabriella B Gajdos; Nicholas F LaRusso; Maria J Perugorria; Jesus M Banales; Sergio A Gradilone
Journal:  Hepatology       Date:  2018-05-21       Impact factor: 17.425

3.  LncRNA FENDRR represses proliferation, migration and invasion through suppression of survivin in cholangiocarcinoma cells.

Authors:  Xinglei Qin; Min Lu; Yajun Zhou; Gang Li; Zhaoyang Liu
Journal:  Cell Cycle       Date:  2019-04-14       Impact factor: 4.534

Review 4.  Pathology of Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma.

Authors:  Murli Krishna
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

Review 5.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

6.  Intrahepatic cholangiocarcinoma, are we making progress?

Authors:  Andre Gorgen; Nicolas Goldaracena; Wei Zhang; Gonzalo Sapisochin
Journal:  Hepatobiliary Surg Nutr       Date:  2018-04       Impact factor: 7.293

7.  Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma.

Authors:  Hongchen Zhang; Zhizhen Li; Bingfeng Chu; Fei Zhang; Yijian Zhang; Fayong Ke; Yuanyuan Chen; Yi Xu; Shibo Liu; Shuai Zhao; Haibin Liang; Mingzhe Weng; Xiangsong Wu; Maolan Li; Wenguang Wu; Zhiwei Quan; Yingbin Liu; Yong Zhang; Wei Gong
Journal:  Tumour Biol       Date:  2016-01-04

8.  Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.

Authors:  Miguel Garcia-Pardo; Laura Ortega; María Jesús Fernández-Aceñero; Pilar García Alfonso; Miguel Martín; Andrés J Muñoz
Journal:  J Gastrointest Cancer       Date:  2021-03-08

Review 9.  A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population.

Authors:  David Kim; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 10.  Early detection of intrahepatic cholangiocarcinoma.

Authors:  Mami Hamaoka; Kazuto Kozaka; Osamu Matsui; Takahiro Komori; Takashi Matsubara; Norihide Yoneda; Kotaro Yoshida; Dai Inoue; Azusa Kitao; Wataru Koda; Toshifumi Gabata; Satoshi Kobayashi
Journal:  Jpn J Radiol       Date:  2019-08-01       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.